Evaluation of the DPP HIV 1/2 Test and the HIV 1/2 Stat Pak Test Using Oral Fluid (HIVOF)
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
![](https://webarchive.library.unt.edu/web/20130317082216im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
This protocol is intended to test the feasibility of using the HIV 1/2 STAT-PAK and the DPP HIV 1/2 test (with and without the DPP Handheld Reader) to detect HIV antibodies in oral fluids.
Condition |
---|
HIV Infections |
Study Type: | Observational |
Study Design: | Observational Model: Case-Only Time Perspective: Cross-Sectional |
Official Title: | Evaluation of the DPP HIV Test With Reader and the HIV 1/2 Stat-Pak Test Using Oral Fluids |
- Number of Fresh Oral Fluid Samples With Known HIV (+) Status and HIV Reactivity [ Time Frame: 1 to 3 days ] [ Designated as safety issue: No ]
- The Effectiveness of MPC and Chembio Oral Fluid Collection Devices [ Time Frame: 1-3 ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples Without DNA
oral fluid samples and venous blood
Enrollment: | 101 |
Study Start Date: | March 2008 |
Study Completion Date: | July 2008 |
Primary Completion Date: | July 2008 (Final data collection date for primary outcome measure) |
Groups/Cohorts |
---|
A, Observational |
Detailed Description:
The objective of this study is to evaluate the feasibility of using fresh oral fluid specimens, from known HIV-positive individuals, to test for HIV-1 antibodies using both the DPP HIV 1/2 and HIV 1/2 STAT-PAK tests. Two oral fluid collection devices will be used and compared (MPC and Chembio collection devices) and the results obtained from oral fluids will be compared with those obtained from whole blood and plasma using paired samples from the same participants. The comparison between oral fluid, whole blood and plasma will be made in both Chembio devices (HIV 1/2 STAT-PAK and DPP HIV 1/2).
![](https://webarchive.library.unt.edu/web/20130317082216im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
Ages Eligible for Study: | 12 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
The study population consists of 100 participants with known (clinically or serologically) confirmed HIV infection. The participants, recruited by the staff of the Laboratory of Vial Diagnostics from the Evelyn Jordan Center, may be males or females (including pregnant women) at least 12 years of age from any ethnic and racial background.
Inclusion Criteria:
- Participants with known HIV infection who are willing to participate in the study and who sign an informed consent (or assent), will be included in the study.
- Patients on HAART treatment for HIV will be included, but this information as well as the dates (duration) of treatment will be obtained through the interview of study participants; a medical record review is not necessary or required. The study participant's responses will be recorded by study staff on a Data Collection Form.
- Patients with immunosuppressive conditions other than HIV will be included if available, but will be limited to < 25% of the total test population. Immunosuppression will also be assessed through interview of study participants and/or through verbal confirmation by the treating physician; a medical record/chart review is not required.
- Patients must be willing to undergo venipuncture to donate one tube of EDTA whole blood (not more than 10cc), and to provide three oral fluid samples.
Exclusion Criteria:
- Patients who do not consent, withdraw consent, or for whom the investigator determines that venipuncture or gum swabbing may create a health risk will be excluded from the study.
- Participants who have been enrolled in HIV vaccine studies will be excluded from the study. This will be ascertained through interview of study participants.
- Participants who have been enrolled once in this study will be excluded from repeat enrollment.
- Participants must not have introduced any substance into their oral cavity (gum, food, beverage, candy, lozenges, mouthwash, etc.) for 30 minutes prior to providing an oral fluid sample. This will be ascertained through interview of study participants.
![](https://webarchive.library.unt.edu/web/20130317082216im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
United States, Maryland | |
Evelyn Jordan Center, University of Maryland | |
Baltimore, Maryland, United States, 21201 |
Principal Investigator: | Niel Constantine, PhD | University of Maryland |
![](https://webarchive.library.unt.edu/web/20130317082216im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
No publications provided
Responsible Party: | Thomas D. Ippolito, Chembio Diagnostic Systems, Inc |
ClinicalTrials.gov Identifier: | NCT00636220 History of Changes |
Other Study ID Numbers: | P-HIV-01, UMB Protocol # H-29110 |
Study First Received: | March 10, 2008 |
Results First Received: | January 8, 2009 |
Last Updated: | January 20, 2010 |
Health Authority: | United States: Institutional Review Board |
Keywords provided by Chembio Diagnostic Systems, Inc.:
HIV-1 Infections |
Additional relevant MeSH terms:
HIV Infections Acquired Immunodeficiency Syndrome Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases |
Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Slow Virus Diseases |
ClinicalTrials.gov processed this record on March 14, 2013